54
Participants
Start Date
February 28, 2010
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
Bendamustine
Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
Rituximab
Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
Hematology Oncology Physicans Extenders Group, Tucson
University of Arkansas for Medical Sciences, Little Rock
St. Jude Heritage Medical Group, Fullerton
Comprehensive Cancer Center, Palm Springs
University of Colorado Cancer Center, Aurora
Rocky Mountain Cancer Center, Denver
The Hospital of Central Connecticut, New Britain
Cancer Center of Central Connecticut, Southington
Memorial Cancer Institute, Hollywood
Cancer Centers of Florida, Orlando
MD Anderson Cancer Cnt Orlando, Orlando
John B Amos Cancer Center, Columbus
St Francis Cancer Research Foundation, Beech Grove
Cedar Valley Medical Specialists, Waterloo
Cancer Center of Kansas, Wichita
University of Kentucky, Lexington
LSU Health Sciences Center - Shreveport, Shreveport
MaineGeneral Medical Center, Augusta
Missouri Cancer Associates, Columbia
Kansas City Cancer Center, Kansas City
UNM Cancer Center/New Mexico Cancer Care Alliance, Albuquerque
Interlakes Foundation, Inc, Rochester
SUNY Upstate / Upstate Medical University, Syracuse
Willamette Valley Cancer Center, Springfield
Geisinger Medical Center, Danville
Pennsylvania Oncology Hematology Associates, Inc., Philadelphia
Charleston Hematology Oncology, PA, Charleston
Sarah Cannon Cancer Center, Nashville
Texas Oncology, P.A., Fort Worth
Cancer Care Center of South Texas, San Antonio
Texas Oncology, Tyler
Virginia Oncology Associates, Norfolk
Cancer Outreach Asscociates, PC, Richlands
Cancer Care Northwest-South, Spokane
Northwest Cancer Specialists, PC, Vancouver
West Virginia University School of Medicine, Morgantown
The Canberra Hospital, Garran
Royal Adelaide Hospital, Adelaide
The Queen Elizabeth Hospital, Woodville
Royal Hobart Hospital, Hobart
The Alfred Hospital, Melbourne
Queen Elizabeth II Health Sciences Centre, Halifax
Ottawa Hospital - General Campus, Ottawa
Lead Sponsor
Cephalon
INDUSTRY